Extranodal Rosai-Dorfman Disease- A review of diagnostic testing and management.

Imad ud Deen
Medstar Health Internal Medicine Residency Program, imadud.deen@medstar.net

Abhinandan Chittal
Medstar Health Internal Medicine Residency Program

Nabil Badro
Department of Surgery, Medstar Health, Harbor Hospital

Robert Jones
Department of Pathology, Medstar Health

Christopher Haas
Department of Medicine, Medstar Health

Follow this and additional works at: https://scholarlycommons.gbmc.org/jchimp

Part of the Hematology Commons, Internal Medicine Commons, and the Oncology Commons

Recommended Citation
Deen, Imad ud; Chittal, Abhinandan; Badro, Nabil; Jones, Robert; and Haas, Christopher (2022) "Extranodal Rosai-Dorfman Disease- A review of diagnostic testing and management.," Journal of Community Hospital Internal Medicine Perspectives: Vol. 12: Iss. 2, Article 5.
DOI: 10.55729/2000-9666.1032
Available at: https://scholarlycommons.gbmc.org/jchimp/vol12/iss2/5

This Case Report is brought to you for free and open access by the Journal at GBMC Healthcare Scholarly Commons. It has been accepted for inclusion in Journal of Community Hospital Internal Medicine Perspectives by an authorized editor of GBMC Healthcare Scholarly Commons. For more information, please contact GBMCcommons@gbmc.org.
Extranodal Rosai-Dorfman Disease- a Review of Diagnostic Testing and Management

Imad ud Deen a,*, Abhinandan Chittal a, Nabil Badro b, Robert Jones c, Christopher Haas d,e

a Medstar Health Internal Medicine Residency Program, USA
b Department of Surgery, Medstar Health, Harbor Hospital, USA
c Department of Pathology, Medstar Health, USA
d Department of Medicine, Medstar Health, USA
e Department of Medicine, Georgetown University Medical Center, USA

Abstract

Rosai-Dorfman disease (RDD) is a rare, benign histiocytic proliferative disorder primarily occurring in the lymph nodes. Extranodal disease can occur in skin and soft tissue, central nervous system, gastrointestinal tract, and breast. Here we present a case of a 55-year-old female with a history of hypertension, hyperlipidemia, and diabetes mellitus who presented with a fixed solid mass localized to the right medial thigh. Excision revealed S100 and CD 68 positive scattered lymphoid aggregates and emperipolesis, hallmark molecular and cytopathologic features of RDD. RDD is a nonmalignant, classically sporadic histiocytosis. Clinical outcome in terms of mortality seems to be favorable in most cases, however given the benign and slowly progressive nature of the disease, conservative management with observation is typical, with surgical excision recommended for larger lesions. Currently, therapy revolves around surgical and immunosuppressive treatments, but the optimal diagnostic and therapeutic management of RDD remains to be defined.

Keywords: Rosai-Dorfman disease

1. Background

Rosai-Dorfman disease (RDD), first described as a distinct clinicopathological entity in 1969, is a rare non-malignant disorder characterized by histiocytic proliferation with a prevalence of only 1 in 200,000 in the United States.1,2 The disease predominantly affects children and young adults, with a slight male predominance, and oftentimes displays a chronic, relapsing course.3,4 Patients typically present with fever, leukocytosis, and painless cervical lymphadenopathy. Although RDD has a predilection for the lymph nodes of the head and neck, any nodal region may be affected, and furthermore the disease may also present in extranodal locations including the skin and soft tissue, central nervous system (CNS), gastrointestinal tract, and breast.5–12 In contrast to nodal RDD, extranodal, cutaneous RDD usually presents as slow-growing, painless, nonpruritic nodules, plaques, or papules with coloration varying from yellow to red to brown.13 Emperipolesis, histiocytic phagocytosis of lymphocytes, plasma cells, erythrocytes, or polymorphonuclear leukocyte, is considered to be pathognomonic and remains a critical histopathologic feature, along with S-100 and CD68 positive staining of the histiophagocytic cells.1,14–16 We present a rare case of Rosai-Dorfman disease, an underrecognized and diagnosed entity with limited, albeit emerging diagnostic criteria, heretofore focused on immunohistochemistry of tissue samples. We also explore management options, highlighting both conservative evaluation as well as surgical intervention with periodic surveillance for resolution or recurrence.

2. Case presentation

A 55-year-old woman with a past medical history significant for hypertension, hyperlipidemia, non-insulin dependent diabetes mellitus, and right...
middle cerebral artery infarction managed with mechanical thrombectomy presented with complaints of right thigh swelling. She reported usual health until six months prior to presentation when she noticed a solid mass on the medial aspect of her right thigh. There was no associated pain, redness, or discharge, and no antecedent trauma. Physical examination demonstrated an 11 × 6 cm fixed solid mass localized to the right medial thigh without erythema, crepitus, or ecchymoses. Diagnostic evaluation demonstrated unremarkable serum chemistries. She underwent surgical resection of the mass with gross examination notable for a tan-yellow lesion measuring 6.1 × 4.8 × 2.5 cm surrounded by normal subcutaneous tissue. Tissue pathology demonstrated diffuse, sheet-like proliferation of spindled and epithelioid cells in a background of sclerotic and fibrotic stroma (Fig. 1). Histological analysis revealed involvement of mature adipose tissue and chronic inflammation with the presence of scattered lymphoid aggregates and plasma cells along with histiocytes containing ample eosinophilic granular cytoplasm and intact intracytoplasmic inflammatory cells (“emperipolesis”) (Fig. 2). Immunohistochemical staining was negative for CD34, actin, desmin, beta-catenin, CD1a, and mycobacterial/fungal stains, but notably positive for S100 (Fig. 3) and CD68, further confirming the diagnosis. The patient’s wound was, while large, was closed by primary intention, without tension. She was followed weekly on an outpatient basis with appropriate approximation and closure. She was followed for 6 months, at the time of this report, with no evidence of local recurrence or dehiscence.

3. Discussion

Rosai-Dorfman disease is a rare, benign, idiopathic proliferative disorder affecting histiocytes, typically affecting isolated lymph nodes. Patients present with bilateral, painless, cervical lymphadenopathy with or without constitutional symptoms such as fever, night sweats, and weight loss. Although classically confined to lymph nodes, up to 40% of patients with RDD manifest extra nodal involvement with or
without adenopathy. In contrast to nodal disease, extranodal disease most commonly presents as a painless, palpable mass. It affects females more frequently, with one case series documenting a 90% female predominance. The most frequent extranodal sites were found to be skin and soft tissue (16%); nasal cavity and paranasal sinuses (16%); eye, orbit, and ocular adnexa (11%); bone (11%); salivary gland (7%); central nervous system (7%); oral cavity (4%); kidney and genitourinary tract (3%); respiratory tract (3%); liver (1%); tonsil (1%); and breast (<1%). Our patient’s presentation correlates well with previously reported cases of extranodal RDD, presenting with an insidious, slowly progressing, asymptomatic mass. While the majority of RDD is considered to be nodal in nature, an extensive physical evaluation was performed, yet failed to demonstrate any evidence of lymphatic swelling. While some patients with RDD have adjunctive constitutional symptoms — fever, night sweats, weight loss — this is not considered to be exclusive and may raise the specter of an alternative diagnosis such as a lymphoproliferative disease. Our patient did not experience any of these symptoms and our suspicion for an alternative diagnosis, prior to histological sampling, remained low.

The presence of nonspecific symptoms such as fever, leukocytosis, weight loss, and cervical lymphadenopathy in individuals with RDD may mimic a variety of lymphoproliferative disorders: Hodgkin’s and non-Hodgkin’s lymphoma, Langerhans cell histiocytosis, granulomatous lymphadenitis, reactive lymphadenopathy, Castleman’s Disease, and Kikuchi-Fujimoto disease — making histopathology a key feature of diagnosis. Histologically, RDD is characterized not only by histiocytic proliferation, but also histiocyte-mediated phagocytosis of intact lymphocytes and other immune cells, leading to the disease’s histological hallmark finding, emperipolysis. These histiocytes are typically positive for S-100 and CD68 antigens and negative for CD1a immunohistochemical staining and BRAF V600E mutations. These findings are used to differentiate RDD from Langerhans’s cell histiocytosis and Erdheim-Chester Disease, in which the histopathological findings are characterized by a lack of emperipolysis and the presence of Langerhans’ cells and foamy histiocytes. Furthermore, these disorders appear to have unique immunohistochemical signatures: S100-negative, CD68-positive, CD1a negative, and BRAF V600E positive cells in Erdheim-Chester; S100-positive, CD68-positive, CD1a positive, and BRAF V600E positive cells in Langerhans’s cell histiocytosis.

The pathogenesis of RDD remains unknown. Infection by human herpes virus-6 (HHV-6), Epstein-Barr virus (EBV), and Parvovirus B19 have been suspected as instigating events. Several genetic mutations have also been identified recently including mutations in ARAF, MAP2K1, NRAS, and KRAS. KRAS and MAP2K1 are associated with 33% of RDD cases, suggesting that the RAS-MAP2K1 pathway may be an integral component of disease development and thus a potential therapeutic target.

Of note, our patient had an initial breast biopsy demonstrating CD68-positive cells, which while not specific, could have raised suspicion for extranodal, breast RDD, specifically if additional staining for S-100 (positive) and the absence of a BRAF V600E mutation were noted. However, at the time she was diagnosed with benign histiocytic infiltration without further follow up. While likely unrelated, RDD of the breast may mimic fat necrosis on core biopsy. She subsequently presented with soft tissue swelling on the medial aspect of the thigh, which was removed surgically with subsequent histopathological findings consistent with RDD. Review of cases with RDD involving the CNS show a 15% recurrence rate after surgery, though no literature has been reported regarding recurrence of cutaneous RDD.

The diagnostic and staging evaluation of patients with newly diagnosed RDD should include an assessment of disease extent, as well as evaluation for conditions either known to be associated with RDD, particularly autoimmune disorders, or known to contain a component of reactive histiocytosis. CT of the neck, chest, abdomen, and pelvis is recommended. RDD lesions are known to be FDG-avid, including extra nodal areas and FDG-PET/CT is used by some investigators for initial staging when possible. Biopsy is required for confirmatory diagnosis.

RDD resolves spontaneously in approximately 20%–50% of the cases, however a minority of patients may develop organ dysfunction due to massive nodal enlargement resulting in fatal disease. Treatment is warranted to halt the natural progression of RDD in such cases. Therapeutic options for RDD include corticosteroid therapy, surgery, radiation therapy and biologics. The natural history of the disease is uncertain, however, the reported mortality rate is about 7%; with concomitant presence of immune dysfunction. Emerging data suggests that given the low rate of mortality, even in the absence of intervention, more patients are electing conservative management with observation as opposed to surgical excision;
however given that our patient had a large mass, surgical excision was the treatment of choice.

4. Conclusion

Rosai-Dorfman Disease is a rare, benign histoproliferative disease mainly affecting the lymph nodes of the head and neck, however the disease may manifest in alternative lymphatic groups as well as extranodal sites, including the skin. Confirmatory diagnosis is done by biopsy with histopathological and immunostaining, with classic demonstration of histiocytic proliferation, histioocyte-mediated phagocytosis of intact lymphocytes and other immune cells, and positive staining for S-100 and CD68 antigens. While the disease may resolve spontaneously, surgical excision is recommended for larger tumor burden.

Declaration of competing interest

There is no conflict of interest.

References

1. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969;87(1):63–70.
2. Mahzoni P, Zavareh MHT, Bagheri M, Hani N, Moqtader B. Intracranial ROSAI-DORFMAN disease. J Res Med Sci. 2012;17(3):304–307.
3. Lim R, Wittram C, Ferry JA, Shepard JAO. FDG PET of Rosai-Dorfman disease of the thymus. AJR Am J Roentgenol. 2004;182(2):514. https://doi.org/10.2214/ajr.182.2.1820514.
4. Woodcock RJ, Mandell JW, Lipper MH. Sinus histiocytosis (Rosai-Dorfman disease) of the suprasellar region: MR imaging findings—a case report. Radiology. 1999;213(3):808–810. https://doi.org/10.1148/radiology.213.3.9911308.
5. Cooper SL, Jenrette JM. Rosai-Dorfman disease: management of CNS and systemic involvement. Clin Adv Hematol Oncol. 2012;10(3):199–202.
6. Frater JL, Maddox JS, Obadiah JM, Hurley MY. Cutaneous Rosai-Dorfman disease: comprehensive review of cases reported in the medical literature since 1990 and presentation of an illustrative case. J Cutan Med Surg. 2006;10(6):281–290. https://doi.org/10.1016/j.jcms.2006.06.007.
7. Kong YY, Kong JC, Shi DR, et al. Cutaneous rosai-dorfman disease: a clinical and histopathologic study of 25 cases in China. Am J Surg Pathol. 2007;31(3):341–350. https://doi.org/10.1097/01.pas.0000213387.70783.6c.
8. McClellan SF, Ainbinder DJ. Orbital Rosai-Dorfman disease: a literature review. Orbit. 2013;32(5):341–346. https://doi.org/10.3109/01676830.2013.814689.
9. Purav P, Ganapathy K, Mallikarjuna VS, et al. Rosai-Dorfman disease of the central nervous system. J Clin Neurol. 2005;12(6):656–659. https://doi.org/10.1016/j.jocn.2005.06.003.
10. Sandoval-Sus JD, Sandoval-Leon AC, Chapman JR, et al. Rosai-Dorfman disease of the central nervous system: report of 6 cases and review of the literature. Medicine (Baltimore). 2014;93(3):165–175. https://doi.org/10.1097/MD.0000000000000039.
11. Zhao M, Li C, Zheng J, et al. Extranodal Rosai-Dorfman disease involving appendix and mesenteric nodes with a protracted course: report of a rare case lacking relationship to IgG4-related disease and review of the literature. Int J Clin Exp Pathol. 2013;6(11):2569–2577.
12. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1996;7(1):19–73.
13. Al-Khaeteeb THH. Cutaneous rosai-dorfman disease of the face: a comprehensive literature review and case report. J Oral Maxillofac Surg. 2016;74(3):528–540. https://doi.org/10.1016/j.oms.2015.09.017.
14. Rastogi V, Sharma R, Misra SR, Yadav L, Sharma V. Emperipolesis - a review. J Clin Diag Res. 2014;8(12). https://doi.org/10.7860/jcdr/2014/1265299. ZM01-02.
15. Kata IO, Ergin M, Sahin B, Inal S, Tasova Y. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman’s disease) previously misdiagnosed as Toxoplasma Lymphadenitis. Leuk Lymphoma. 2004;45(5):1037–1041. https://doi.org/10.1080/1042819031000149540.
16. Carbone A, Passanante A, Gloghini A, Devaney KO, Rinaldo A, Fertlito A. Review of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) of head and neck. Ann Otol Rhinol Laryngol. 1999;108(11 Pt 1):1095–1104. https://doi.org/10.1177/000348999910801113.
17. Gaitonde S. Multifocal, extranodal sinus histiocytosis with massive lymphadenopathy: an overview. Arch Pathol Lab Med. 2007;131(7):1117–1121. https://doi.org/10.1045/s1-1111-1104. https://doi.org/10.1177/0044033807007011117.
18. Zhu F, Zhang J, Tang X, Wei et, al. Rosai-Dorfman disease: a retrospective analysis of 13 cases. Am J Med Sci. 2013;345(3):200–210. https://doi.org/10.1097/MAJ.0b013e3182553ec2d.
19. Saboo SS, Jagannathan JP, Krajewski KM, et al. Symptomatic extranodal Rosai-Dorfman disease treated with steroids, radiation, and surgery. J Clin Oncol. 2011;29(31):772–775. https://doi.org/10.1200/JCO.2011.36.9967.
20. Mantilla JJG, Goldberg-Stein S, Wang Y. Extranodal rosai-dorfman disease: clinicopathologic series of 10 patients with radiologic correlation and review of the literature. Am J Clin Pathol. 2011;135(2):211–221. https://doi.org/10.1093/ajcp/aqr029.
21. Bi Y, Hua Z, Meng Y, et al. Extranodal Rosai-Dorfman disease involving the right atrium in a 60-year-old male. Diagn Pathol. 2014;9(1):115. https://doi.org/10.1186/1746-1596-9-115.
22. Najafi-Sani M, Saneian H, Mahjoub F. Rosai-Dorfman Disease with nodal and extranodal involvements: a case report. J Res Med Sci. 2011;16(9):1251–1256.
23. Yoon AJ, Parisien M, Feldman F, Young-In Lee F. Extranodal Rosai-Dorfman disease of bone, subcutaneous tissue and paranasal sinus mucosa with a review of its pathogenesis. Skeletal Radiol. 2005;34(10):653–657. https://doi.org/10.1007/s00256-005-0953-4.
24. Bruce-Brand C, Schneider JW, Schubert P. Rosai-Dorfman disease: an overview. J Clin Pathol. 2020;73(11):697–705. https://doi.org/10.1136/jclinpath-2020-206733.
25. Lu D, Estillilla OC, Manning JT, Medeiros LJ. Sinus histiocytosis with massive lymphadenopathy and malignant lymphoma involving the same lymph node: a report of four cases and review of the literature. Mod Pathol. 2008;21(4):414–419. https://doi.org/10.1038/modpathol.2007.135.
26. Ioachim H, Medeiros J. Ioachim’s lymph node pathology. 4th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2009.
27. Kenn W, Eck M, Allolio B, et al. Erdheim-Chester disease: evidence for a disease entity different from Langhans cell histiocytosis? Three cases with detailed radiological and immunohistochemical analysis. Hum Pathol. 2000;31(6):734–739. https://doi.org/10.1016/s0046-8177(00)00029-1.
28. Tsang WY, Chan JK, Ng CS. Kikuchi’s lymphadenitis. A morphologic analysis of 75 cases with special reference to unusual features. Am J Surg Pathol. 1994;18(3):219–231.
29. Lima FB, Barcelos PS de V, Constão APN, Nogueira AL, Melo-Filho AA. Rosai-Dorfman disease with spontaneous resolution: case report of a child. Rev Bras Hematol Hemoter. 2011;33(4):312–314. https://doi.org/10.5581/1516-4848.20110083.
30. Ha H, Kim KH, Ahn YJ, Kim JH, Kim JE, Yoon SS. A rare case of Rosai-Dorfman disease without lymphadenopathy. Korean J Intern Med (Engl Ed). 2016;31(4):802–804. https://doi.org/10.3904/kjim.2015.026.

JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES 2022;12:18–22

CASE REPORT
31. Dalia S, Sagatys E, Sokol L, Kubal T. Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014;21(4):322–327. https://doi.org/10.1177/107327481402100408.

32. Mehraein Y, Wagner M, Remberger K, et al. Parvovirus B19 detected in Rosai-Dorfman disease in nodal and extranodal manifestations. J Clin Pathol. 2006;59(12):1320–1326. https://doi.org/10.1136/jcp.2005.029850.

33. Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154–165. https://doi.org/10.1158/2159-8290.CD-15-0913.

34. Garces S, Medeiros LJ, Patel KP, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017;30(10):1367–1377. https://doi.org/10.1038/modpathol.2017.55.

35. Matter MS, Bihl M, Juskevicius D, Tzankov A. Is Rosai-Dorfman disease a reactive process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease. Virchows Arch. 2017;471(4):545–547. https://doi.org/10.1007/s00428-017-2173-4.

36. Jacobsen E, Shanmugam V, Jagannathan J. Rosai–Dorfman disease with activating KRAS mutation — response to cibimetinib. N Engl J Med. 2017;377(24):2398–2399. https://doi.org/10.1056/NEJMct1713676.

37. Chen X. 115 rosai–dorfman disease of the breast mimicking fat necrosis on core biopsy. Am J Clin Pathol. 2018;149(suppl_1):S49. https://doi.org/10.1093/ajcp/aqx118.114.

38. Rivera D, Pérez-Castillo M, Fernández B, Stoeter P. Long-term follow-up in two cases of intracranial Rosai-Dorfman Disease complicated by incomplete resection and recurrence. Surg Neurol Int. 2014;5(1):30. https://doi.org/10.4103/2152-7806.128003.

39. Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131(26):2877–2890. https://doi.org/10.1182/blood-2018-03-839753.

40. Albano D, Bosio G, Bertagna F. 18F-FDG PET/CT follow-up of rosai-dorfman disease. Clin Nucl Med. 2015;40(8):e420–e422. https://doi.org/10.1097/RLU.0000000000001853.

41. Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483–492. https://doi.org/10.1182/blood-2014-03-561381.

42. Pulsoni A, Anghel G, Falcucci P, et al. Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review. Am J Hematol. 2002;69(1):67–71. https://doi.org/10.1002/ajh.10008.

43. Abou-Zeid AH, Herwadkar A, du Plessis D, Gnanalingham KK. Isolated extradural Rosai-Dorfman disease of the thoracic spine: a rare cause of spinal cord compression: case report. Neurosurgery. 2010;67(2):E514–E515. https://doi.org/10.1227/01.NEU.0000372203.38326.

44. Zhou LF, Chen L, Zhu Q, et al. Unusual life-threatening Rosai-Dorfman disease of the trachea: role of NF-κB. Thorax. 2010;65(10):927–929. https://doi.org/10.1136/thx.2010.139998.

45. Delaney, MD EE, Larkin, MD A, MacMaster, MD S, Sakhdari, MD A, DeBenedictis, CM D. Rosai-Dorfman disease of the breast. Cureus. Published online April 11, 2017. https://doi.org/10.7759/cureus.1153